Pathophysiologic and pharmacokinetic determinants of the antihypertensive response to propranolol by Esler, Murray et al.
Pathophysiologic and pharmacokinetic determinants of 
the antihypertensive response to propranolol 
The tendency for patients with essential hypertension to differ markedly in 
antihypertensive response to propranolol could arise from pathophysiologic or 
pharmacokinetic differences between them. This possibility was investigated in 23 men 
with mild to moderately severe essential hypertension. At each of three propranolol doses, 
40 mg, 80 mg, and 320 mg daily, approximately a 20-fold range in steady-state plasma 
propranolol concentrations was observed. Clinical response however was unrelated to 
plasma propranolol: oral dose ratio, since patients with higher plasma levels were less 
sensitive to the existing plasma drug concentration. When falls in blood pressure and 
plasma propranolol concentration were compared overall, a biphasic dose-response 
relationship was noted, with a first component at plasma propranolol concentrations of 3 
to 30 ng Iml and a second at concentrations above 30 ng Iml. Only patients with increased 
sympathetic nervous system activity and high plasma renin activity (PRA) had substantial 
falls in pressure at propranolol levels of 3 to 30 nglml. Cardiac beta adrenergic receptor 
blockade, not suppression of PRA, seemed to be the antihypertenisve mechanism. This 
relation of pretreatment sympathetic nervous activity and PRA to antihypertensive 
response existed only at lower plasma propranolol concentrations. With a propranolol 
dose of 320 mg daily, both plasma norepinephrine concentration and PRA were unrelated 
to the clinical response. 
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Patients with essential hypertension show 
widely differing sensitivity to the blood 
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pressure-lowering effect of beta adrenoceptor 
blocking drugs,24 Attempts to explain this 
phenomenon have focused on presumed differ-
ences in the pathophysiology of the essential 
hypertension. Early reports emphasized a high 
cardiac output,10 increased plasma renin activ-
ity,l and enhanced sympathetic nervous system 
responsiveness6 as predictors of a good an-
tihypertensive response to beta adrenoceptor 
blockers and reduction in cardiac output, 
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Fig. 1. Relation of fall in blood pressure to plasma propranolol concentration. Mean val-
ues ± standard errors are plotted for the logarithmic plasma propranolol intervals < 2 ng/ml, 2 to 
4, 4 to 8, 8 to 16, ... 256 to 512 ng/m!. Each point, except for the highest propranolol value, 
is based on a minimum of five observations. 
plasma renin activity, and sympathetic nervous 
activity as blood pressure-lowering mecha-
nisms. Subsequent studies by other workers 
have often failed to confirm the earlier 
findings,5, 18, 22 which generates widespread 
confusion as to the mechanism by which beta 
adrenoceptor blocking drugs reduce blood 
pressure and the degree of predictability of the 
response. 
Frequently in such studies observations on 
plasma drug concentrations have not been re-
ported. With propranolol, patients achieve 
widely differing plasma concentrations on a 
given dose,23 thus phannacokinetic factors are 
potentially an important source of variability in 
the blood pressure response. In our study we 
evaluated the relative importance of pathophys-
iologic factors and differences in plasma 
propranolol concentration as determinants of 
the magnitude of the antihypertensive response 
to propranolol in patients with essential hyper-
tension. Of the possible pathophysiologic 
determinants, abnormal plasma renin status 
and increased sympathetic nervous system 
activity were thought to be most relevant and 
were selected for investigation. 
Methods 
The study was performed in 23 men, aged 18 
to 58 yr, with untreated mild to moderately se-
vere essential hypertension. Pretreatment blood 
pressure was ISS to 185 mm Hg systolic, 95 to 
125 mm Hg diastolic, or both. No patient had 
grade III or grade IV hypertensive retinopathy 
or a serum creatinine above I. 6 mg/ 100 m\. 
Secondary hypertension was adequately ex-
cluded by clinical testing which included an 
intravenous pyelogram and measurement of 
urinary aldosterone excretion. Prior to the 
commencement of the drug trial, patients were 
admitted to hospital for investigation of the 
pathophysiology of essential hypertension. 
Tests were performed in a metabolic ward on 
the patients in sodium balance after a minimum 
of 5 days on a daily sodium intake of 160 mEq. 
After the patients had been standing for I hr, 
blood was drawn for estimation of plasma renin 
activity (PRA) by radioimmunoassay. 11 Plasma 
renin activity in relation to urinary sodium 
excretion was referred to the limits of normality 
for the PRA-dietary sodium relationship1 estab-
lished in 41 age-matched normal male volun-
teers. Plasma renin activity was elevated in 7 
patients, normal in 10, and low in 6. In patients 
with low PRA, plasma renin subsequently re-
mained suppressed after 6 days of sodium de-
privation (10 mEq sodium daily). This plasma 
renin distribution was a consequence of selec-
tive recruitment for the study, based on earlier 
clinical renin typing, such as to give approxi-
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Fig. 2. Relation of plasma propranolol concentration to oral dose of drug. 
mately equal numbers of patients in each renin 
subgroup. 
On a second day, after a minimum of I hr of 
supine rest, blood was drawn via an indwelling 
intravenous catheter for estimation of plasma 
norepinephrine concentration. The sample was 
assayed "blind" by one of us (Y. DeQ), with-
out knowledge of the diagnosis, with the use 
of the sensitive fluorimetric method of Renzini 
and associates. 19 Hemodynamic measurements 
were performed at rest in all patients. Attention 
was directed specifically at hemodynamic indi-
ces related to sympathetic nervous system activ-
ity. After antecubital brachial artery puncture 
for arterial dye sampling and transvenous cathe-
terization of the right atrium for dye delivery, 
cardiac output was determined by dye dilution 
with the use of indocyanine green. Heart rate 
was read from the electrocardiogram. Stroke 
volume was calculated from cardiac output and 
heart rate. Cardiac systolic time intervals were 
derived from the electrocardiograph, the phono-
cardiograph, and the external carotid arteri-
al pressure tracings. 12 These were expressed 
as systolic time indices by adjusting for the 
influence of heart rate. 12 Mean left ventricular 
ejection rate was calculated from stroke volume 
index and left ventricular ejection time. Plasma 
norepinephrine concentration and hemody-
namics at rest were also measured under 
identical conditions of sodium balance in II 
male normotensive subjects 18 to 45 yr of 
age. Results obtained were used as norms for 
comparison with the values in hypertensive 
patients. 
The drug trial part of the study was per-
formed after completion of physiologic testing. 
The following treatment regimen was instituted 
after a minimum of 4 wk with no antihyperten-
sive medication: placebo for 2 wk and pro-
pranolol, 10 mg 4 times daily for 4 wk, 20 mg 4 
times daily for 4 wk, and 80 mg 4 times daily 
for 4 wk. The trial was single blind. Patients 
attended the clinic between 8 and 10 A.M. after 
2 wk on placebo and at the end of each 4-wk 
dosage period. Blood pressure and pulse rate 
were recorded with the patient supine (mean of 
three observations) after 3 min of rest. Blood 
was drawn 1 to 3 hr after the morning dose for 
estimation of plasma propranolol concentration 
with the use of a fluorimetric method20 (per-
formed by Ayerst Laboratories). After 1 hr 
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Fig. 3. Influence of differences in pharmacokinetics on sensitivity to the antihypertensive effect of 
propranolol. Patients falling in the upper and lower quartile for plasma propranolol: oral dose ratio 
are plotted separately. Each point is based on a minimum of three observations. 
Table I. Influence of differences in pharmacokinetics on the antihypertensive response to 
propranolol 
Propranolol, 
40 mg daily 
Plasma 
propranolol 
concentra-
Parameter tion (ng/ml) 
Patient plasma 
Propranolol/ dose status 
Change in 
mean BP 
(%) 
Propranolol, Propranolol, 
80 mg daily 320 mg daily 
Plasma Plasma 
propranolol Change in propranolol Change in 
concentra- mean BP concentra- mean BP 
tion (ng/ml) (%) tion (ng/ml) (%) 
Lower quartile I ± 3 -2.3±5.1 7±13 -7.1 ± 7.4 47 ± 29 -14.1 ± 5.4 
(n = 6) 
Upper quartile 4 ± 2 -2.2 ± 1.9 36 ± 24* -4.0 ± 3.6 232 ± 57t -11.3 ± 5.8 
(n = 6) 
Mean values and standard deviations are listed. The significance of any difference between the 2 groups is indicated. 
*p < 0.05. 
tp < 0.01, Student's t test. 
standing, venous blood was drawn for estima-
tion of PRA. 
Results 
The relation between plasma propranolol 
concentration and fall in blood pressure for all 
patients combined, which appears to be 
biphasic, is shown in Fig. 1, with an early an-
tihypertensive response, almost complete at a 
plasma propranolol concentration of 10 ng/ml, 
and a later component at plasma propranolol 
concentration above 30 ng/ml. In these patients 
with mild to moderately severe hypertension the 
blood pressure response seemed to plateau at 
plasma propranolol concentrations above 100 
ng/ml. 
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Fig. 4. Fall in blood pressure (o/c) expressed in relation to plasma renin status. The significance of 
any differences in blood pressure fall between patients with normal PRA and those with high or low 
plasma renin is indicated (Student's t test). 
As expected23 at a given oral dose large dif-
ferences between subjects in plasma proprano-
lol concentration were noted (Fig. 2). Since 
plasma propranolol concentration and fall in 
blood pressure were related overall, it was rele-
vant to investigate whether patients with the 
lowest plasma propranolol levels at a given 
dose had the poor therapeutic responses. Dif-
ferences between patients in the plasma pro-
pranolol level achieved by oral dosing, how-
ever, was found not to be a determinant of an-
tihypertensive response. When patients in the 
upper and lower quartile for plasma proprano-
101: oral dose ratio were compared, the fall in 
blood pressure at each propranolol dose in the 2 
groups was similar (Table I). Thus when blood 
pressure fall and plasma propranolol concentra-
tion are compared, patients with the lowest 
plasma propranolol: oral dose ratio appear to 
have greater sensitivity to the existing plasma 
drug levels (Fig. 3). 
The relation of plasma renin status to an-
tihypertensive response is shown in Fig. 4. * At 
low doses of the drug only patients with ele-
vated PRA had greater blood pressure decrease 
with propranolol than those with normal or low 
plasma renin. At plasma propranolol concen-
trations of 3 to 30 ng/ml, the fall in blood 
pressure in the high-renin hypertensive patients 
was approximately double that in the other 2 
renin subgroups (Fig. 4), but at plasma pro-
pranolol concentrations above 30 ng/ml renin 
status did not correlate with antihypertensive 
effect of the drug. 
The dose-response relationships for lowering 
of PRA, heart rate at rest, and blood pressure 
are compared in Fig. 5. The early component of 
the antihypertensive effect of propranolol, at 
*The 4 patients with plasma propranolol concentration above 200 
ng/ml (on 320 mg propranolol daily; Fig. 2) were excluded from this 
analysis to minimize distortion arising from differences in pharma-
cokinetics, since dose-response relationships in such patients fall on 
a different curve than those in most subjects. 23 Of these 4, I had 
high PRA while PRA was normal in 3. Plasma renin status was 
unrelated to plasma propranolol: oral dose ratio. 
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Fig. 5. Relation between plasma propranolol concentration and reduction in blood pressure, plasma 
renin activity, and supine heart rate. 
plasma concentrations of 3 to 30 ng/ml, coin-
cided with maximum suppression of PRA and 
heart rate. The late component of the blood 
pressure fall occurred at a plasma concentration 
well in excess of that necessary to suppress 
PRA and heart rate maximally. 
Since the early component of the antihyper-
tensive response was accentuated in patients 
with elevated PRA and occurred at a plasma 
propranolol concentration causing maximal 
suppression of plasma renin, it was of interest 
to see whether changes in blood pressure and 
PRA correlated at plasma propranolol concen-
trations of 3 to 30 ng/m!. There was a correla-
tion, but of low order only (r = 0.39, 
P < 0.05). It appears that renin suppression, as 
an antihypertensive mechanism, cannot explain 
the relationship of renin status to blood pressure 
decrease at low plasma propranolol levels. 
An alternative explanation of the greater 
pressure decrease in high-renin patients was 
sought in a possible relation of high PRA to 
sympathetic nervous overactivity.3, 7. 21 Com-
pared with normal subjects and hypertensive pa-
tients with normal or low PRA, the high-renin 
hypertensive patients were characterized as a 
group by features of sympathetic nervous sys-
tem overactivity such as elevated plasma nor-
epinephrine concentration, higher cardiac out-
put and heart rate, shortened cardiac pre-
ejection period index, and increased mean left 
ventricular ejection rate (Table II). When the 7 
patients with elevated plasma norepinephrine 
concentration (above 210 ng/L) were compared 
with those with normal plasma norepinephrine, 
an enhanced antihypertensive effect of pro-
pranolol was noted in the former which was 
most prominent with systolic pressure and again 
only at a plasma propranolol concentration of 3 
to 30 ng/ml (Fig. 6). 
Discussion 
When the blood pressure decrease with pro-
pranolol was related to plasma concentration of 
the drug, the dose-response relationship ap-
peared to be biphasic. Approximately 30% of 
the maximum blood pressure fall occurred at a 
plasma propranolol concentration below 20 
ng/m!. A second component of the antihyper-
tensive response was noted at plasma proprano-
Volume 22 
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Fig. 6. Fall in systolic blood pressure (%) expressed in relation to pretreatment plasma norepineph-
rine concentration. The fall in pressure was greater in patients with elevated plasma norepinephrine 
concentration at plasma propranolol levels of 3 to 30 ng/ml. 
Table II. Indices of sympathetic nervous system activity in patients with high-renin essential 
hypertension 
Cardiac hemodynamics at rest 
Plasma Plasma Systolic time Mean left 
renin norepineph- indices ventricular 
activity, rine con- Cardiac Heart ejection 
standing centration index rate/ PEP! LVETI rate 
Subjects (ng /mllhr) (ng/L) (L/min/m 2) min (msec) I (msec) (mllsec) 
Normal subjects 2.10 ± 0.52 138 ± 36 2.66 ± 0.32 60 ± 7 130 ± 8 405 ± 16 ISO ± 19 
Essential hypertension subjects 
High-renin 4.82 ± 0.55* 261 ± 47* 3.28 ± 0.57t 69 ± 8t 119 ± 7t 405 ± 16 170 ± 14t 
Normal-renin 2.40 ± 0.61 161 ± 58 2.37 ± 0.33 60 ± 8 130 ± 6 394 ± 21 139 ± 29 
Low-renin 0.96 ± 0.27 101 ± 54 2.30 ± 0.51 55 ± 7 141 ± 7t 396 ± 9 141 ± 45 
PEPI: pre·ejection period index; L VETI: left ventricular ejection time index. Mean values and standard deviations are listed. The significance 
of the differences between values for the hypertension renin subgroups and the normal subjects is indicated. 
*p < 0.01, Student's t test. 
tp < 0.05. 
101 concentrations above 30 ng/ml, with an ap-
parent plateau in the blood pressure response at 
drug concentrations above 100 ng/m!. Our 
findings are in general agreement with the con-
cept of a biphasic dose-response relationship for 
the antihypertensive effect of propranolol, such 
as was recently proposed by Hollifield and as-
sociates. 14 Although a peak blood pressure fall 
seemed to be achieved at a plasma propranolol 
concentration of 100 ng/ ml, the clinical ques-
tion of whether further useful therapeutic effect 
can be achieved in unresponsive severely hyper-
tensive patients by higher doses of the drug was 
not elucidated, 24 because the present study was 
confined to patients with mild to moderately 
severe disease only and the maximum daily 
propranolol dose given was 320 mg. 
When plasma propranolol concentration was 
306 Esler et al. 
measured in these patients and related to oral 
dose, the expected23 wide spread was noted. 
Since there was a significant relationship be-
tween plasma propranolol concentration and 
blood pressure fall overall, it was pertinent to 
determine whether patients with the lowest 
plasma drug level had the poorest therapeutic 
response. This was found not to be the case. At 
a given dose of propranolol, the fall in blood 
pressure was not smaller in patients with lower 
plasma concentrations. 
This anomalous finding of an adequate an-
tihypertensive response coincident with a low 
plasma propranolol concentration seemed to be 
due to the fact that sensitivity to propranolol 
was related to pharmacokinetic characteristics. 
Such a relationship has been noted pre-
viously-subjects with the lowest plasma pro-
pranolol level showing the greater sensitiv-
ity.23 Possible mechanisms advanced to explain 
this observation include more active first-pass 
hepatic biotransformation in patients with low 
plasma propranolol concentrations with produc-
tion of an active metabolite, increased volume 
of distribution of the drug associated with 
greater tissue binding and beta receptor avidity 
and resultant low plasma levels of drug, and 
diminished plasma protein binding causing pro-
portionally more drug to be present in plasma in 
the free state with a reduction in total plasma 
propranolol concentration. 20. 23 Whatever the 
mechanism, it seems that any pharmacokine-
tic differences between patients which cause 
plasma propranolol levels to differ widely are 
not responsible for differences in clinical re-
sponsiveness to propranolol in essential hyper-
tension. 
When possible pathophysiologic predictors 
of the response to propranolol were sought, it 
was found that the blood pressure decrease was 
greatest in patients with high PRA, but only at 
low plasma propranolol concentrations (3 to 30 
ng/ ml). At plasma levels of 30 to 100 ng/ ml 
and above, the magnitude of the blood pressure 
decrement in high-renin hypertensive patients 
did not differ from that in patients with normal 
and low PRA. Since this low-dose component 
of the antihypertensive response to propranolol 
is accentuated in patients with elevated PRA 
Clinical Pharmacology 
and Therapeutics 
and coincides with maximal suppression of 
plasma renin, it would appear to support the 
view that the blood pressure decrease with the 
drug in essential hypertension is a consequence, 
at least in part, of lowering of PRA .1, 14 How-
ever, when changes in blood pressure and PRA 
were compared, the order of correlation was 
low which suggests that renin suppression was 
not a major antihypertensive mechanism even at 
low plasma propranolol concentrations. At drug 
concentrations above 30 ng/ml, blood pressure 
decrements and PRA were totally unrelated. 
Recent studies in patients with mild high-
renin essential hypertension strongly suggest 
that in this condition the blood pressure eleva-
tion is not renin-dependent,5, 21 which is in con-
trast with the situation in severe and accelerated 
essential hypertension in which PRA values are 
higher, with sufficient elevation of plasma an-
giotensin levels to raise blood pressure by direct 
arteriolar constriction. 2, 3 
In mild high-renin essential hypertension the 
elevation of PRA is viewed as secondary to a 
generalized increase in sympathetic nervous 
system activity in what appears to be a 
neurogenic form of hypertension. 3, 4, 21 In our 
study patients with high PRA had mild hyper-
tension, 3 of 7 having isolated systolic hyper-
tension accompanied by features of sympathetic 
nervous system overactivity. Plasma norepi-
nephrine concentration was elevated in high-
renin patients and the hemodynamic findings of 
a higher cardiac output and heart rate, shortened 
cardiac pre-ejection period index, and increased 
mean left ventricular ejection rate suggested the 
presence of sympathetic cardiac stimulation. It 
may be that patients with increased sympathetic 
nervous cardiovascular tone experienced the 
greatest fall in blood pressure with low doses of 
propranolol. In our study, fall in blood pressure 
at low plasma propranolol levels was greatest in 
patients with an elevated pretreatment plasma 
norepinephrine concentration. There are earlier 
reports also of increased sensitivity to low doses 
of other beta adrenoceptor antagonists (prac-
tolol, acebutolol) in patients with essential 
hypertension with increased sympathetic ner-
vous system activity. 6, 9 It is likely that any 
relation there may be between PRA and respon-
Volume 22 
Number 3 
siveness to beta adrenergic blocking drugs is 
incidental to the role of the sympathetic nervous 
system in determining renin status. 4 • 8. 21 
The antihypertensive action of propranolol in 
essential hypertension appears to involve two 
mechanisms l4-a relatively minor mechanism 
at plasma drug levels of 3 to 30 ng/ml and a 
more important action at concentrations in ex-
cess of 30 ng/m!. The low-dose antihyperten-
sive action was accentuated in patients with fea-
tures of sympathetic nervous overactivity and 
high PRA in whom it was responsible for more 
than 50% of the antihypertensive action of the 
drug. The antihypertensive mechanism does not 
appear to be suppression of plasma renin, al-
though this occurs concurrently. A second ac-
tion of propranolol, occurring at similar plasma 
concentrations, is blockade of cardiac beta ad-
renoceptors. It seems possible that in the pa-
tients with sympathetic nervous overactivity 
and high plasma renin there is also an important 
cardiac component which is antagonized at low 
plasma propranolol concentrations. Cardiac 
output and left ventricular ejection rates were 
highest in these patients. An early report by 
Frohlich and associates lO described a re-
lationship between pretreatment cardiac output 
and the antihypertensive response to proprano-
101, but it was not confirmed in most subsequent 
studies. 22 This disagreement may have arisen 
because the relation of cardiac suppression to 
antihypertensive effect depends on patient 
selection, since it occurs only in patients with 
pronounced sympathetic cardiac stimulation 
and is dose-related, demonstrable only at pro-
pranolol doses of approximately 40 to 80 mg 
daily. 
In the majority of patients the antihyperten-
sive effect of propranolol was minimal at 
plasma propranolol concentrations under 30 
ng/ml and appeared only at higher plasma drug 
concentrations. Our study teIls nothing of the 
mechanism of this blood pressure faIl, other 
than that it seems to be independent of lowering 
of PRA and occurs at plasma propranolol con-
centrations in excess of those needed to induce 
near maximal plasma renin suppression. 16 It is 
not clear whether the results obtained bear on 
the possible significance of a second major an-
Determinants of actions of propranolol 307 
tihypertensive mechanism of beta adrenoceptor 
blocking drugs-suppression of sympathetic 
nervous system function. 6. 15 They do not, 
however, appear to support this view, since the 
antihypertensive response to propranolol, at the 
highest dose, was not related to pretreatment 
plasma norepinephrine concentration. 
With the use of pathophysiologic indices, 
prediction of the blood pressure decrease with 
propranolol was possible only at low doses of 
the drug. Since normalization of blood pressure 
in essential hypertension can be achieved in 
most patients at higher doses,24 possible clinical 
benefits arising from the use of plasma renin or 
indices of sympathetic nervous function as aids 
to the individualization of therapy appear to be 
negligible. Clinical rather than pathophys-
iologic criteria probably offer more appropriate 
guidelines for the selection of propranolol 
as the antihypertensive drug of choice in some 
patients with essential hypertension. 13, 25 
We thank Professor Stevo Julius, in whose labora-
tory the physiologic testing was performed. The 
technical assistance of Mrs. Jane Bennett and Miss 
Patricia Rydelek is gratefully acknowledged, 
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